A single-agent therapy provides durable remission rates and a high rate of peripheral neuropathy resolution in patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL), according to a recent study published in Blood (online September 3, 2017; doi:10.1182/blood-2017-05-780049).
Brentuximab vedotin (Adcetris) is a single-agent injection approved for the treatment of patients with systemic ALCL after failure of at least one prior multi-agent chemotherapy regimen. Long-term data are needed to validate the safety and efficacy of this drug.
Barbara Pro, MD, Robert H Lurie Comprehensive Cancer Center (Chicago, IL), and colleagues conducted a phase II trial to evaluate the safety and efficacy of brentuximab vedotin in patients with relapsed or refractory systemic ALCL. Researchers examined the durability of remission, progression-free survival (PFS), overall survival (OS), and safety outcomes of 58 total patients. The median observation period was approximately 6 years from initial treatment with brentuximab vedotin.
Researchers reported that there were no disease progressions beyond 40 months for any of the patients in the trial, and the median OS was not reached.
Among the 66% of patients (n = 38) with complete response to brentuximab vedotin, all continued to demonstrate improved outcomes with neither median OS nor PFS reached. Sixteen of such patients received a consolidative stem cell transplant with median PFS not reached. No other treatments after brentuximab vedotin therapy were received by the 16 patients who were in remission by the study’s conclusion, other than consolidative stem cell transplant.
Additionally, researchers reported that long-term safety outcomes were favorable for patients receiving brentuximab vedotin. Thirty-three patients experienced peripheral neuropathy. However, 91% of these patients (n = 30) had experienced resolution or improvement at their final assessment in the study.
Researchers concluded that, “these final results, demonstrating a high rate of peripheral neuropathy resolution, and durable remissions in a subset of patients with relapsed or refractory systemic ALCL, provide evidence that single-agent brentuximab vedotin may be a potentially curative treatment option.”—Zachary Bessette